Dr. Reddy’s to delay semaglutide supplies due to quality issue, shares hit
Dr. Reddy’s Laboratories has halted commercial supplies of its generic semaglutide due to an impurity discovered during production scale-up. The company stated there is no impact on patient safety for products already on the market, but the delay will affect availability in India and Canada.
Why it matters
As semaglutide is a high-demand drug for diabetes and weight loss, supply chain disruptions and quality control issues have significant implications for both the pharmaceutical market and patient access.
Dr. Reddy’s Laboratories on Thursday (July 9, 2026) said it has halted commercial supplies of its generic semaglutide after an issue associated with the active pharmaceutical ingredient (API) used in the drug, and fresh despatches were likely to resume only towards late October or early November.
The article provides a straightforward business report on a corporate decision and its market impact.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in